Pelthos Therapeutics (PTHS) Return on Capital Employed (2024 - 2026)
Pelthos Therapeutics (PTHS) posted quarterly Return on Capital Employed of 31.66% for Q4 2025, down 35680.0% year-over-year from N/an in Q4 2024, and up 44.7% quarter-over-quarter from 57.26% in Q3 2025.
Pelthos Therapeutics (PTHS) Return on Capital Employed (2024 - 2026) Analysis & Trends
Pelthos Therapeutics' Return on Capital Employed history runs 2 years deep, the most recent figure standing at 31.66% for Q4 2025.
- In Q4 2025, Return on Capital Employed fell 35680.0% year-over-year to 31.66%; the TTM figure through Dec 2025 stood at 31.66% (down 35680.0% YoY), while the FY2025 annual figure was 81.3%, down 30728.0% from the prior year.
- Return on Capital Employed for Q4 2025 stood at 31.66%, up from 57.26% in the prior quarter.
- The five-year high for Return on Capital Employed was 941.14% in Q1 2024, with the low at 1668.73% in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Pelthos Therapeutics | 91.09 Mn | 66.53 Mn | 21.23 Mn | -64.77% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -59.86% |
| Dec 31, 2025 | -31.66% |
| Sep 30, 2025 | -57.26% |
| Jun 30, 2025 | 138.56% |
| Mar 31, 2025 | 188.33% |
| Dec 31, 2024 | 325.14% |
| Sep 30, 2024 | 805.08% |
| Jun 30, 2024 | -1,668.73% |
| Mar 31, 2024 | 941.14% |